Metrion Biosciences has appointed Dr Barry Kenny and Dr Andrew Southan to its Board of Directors. Barry is chief business officer of Heptares Therapeutics, now part of Sosei Group. He was previously vice president, drug discovery at Takeda Cambridge, and commercial director at Paradigm Therapeutics. Andrew joined Metrion as head of commercial operations in October 2016, and was promoted to COO in April 2017. He has over 25 years of experience in ion channel research and development, starting his career at Wyeth Research, followed by postdoctoral studies at Imperial College London.
